BR9510486A - Compostos moduladores de receptores de esteróide e métodos - Google Patents

Compostos moduladores de receptores de esteróide e métodos

Info

Publication number: BR9510486A
Authority: BR; Brazil
Prior art keywords: compounds; steroid receptor; methods; disclosed; modulating compounds
Prior art date: 1994-12-22

Application number

BR9510486A

Other languages

English (en)

Inventor

Luc J Farmer

Lawrence G Hamann

Lin Zhi

Christopher M Tegley

Sarah J West

James E Edwards

David T Winn

Charlotte L F Pooley

Mark E Goldman

Robert J Davis

Todd K Jones

Original Assignee

Ligand Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-22

Filing date

1995-12-13

Publication date

1998-06-02

1995-06-05 Priority claimed from US08/462,643 external-priority patent/US5696130A/en

1995-12-13 Application filed by Ligand Pharm Inc filed Critical Ligand Pharm Inc

1998-06-02 Publication of BR9510486A publication Critical patent/BR9510486A/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Hematology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Quinoline Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Liquid Crystal (AREA)
Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)

BR9510486A 1994-12-22 1995-12-13 Compostos moduladores de receptores de esteróide e métodos BR9510486A (pt)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
US36352994A	1994-12-22	1994-12-22
US08/462,643 US5696130A (en)	1994-12-22	1995-06-05	Tricyclic steroid receptor modulator compounds and methods
US08/464,546 US5693647A (en)	1994-12-22	1995-06-05	Steroid receptor modulator compounds and methods
US08/465,429 US5696127A (en)	1994-12-22	1995-06-05	Steroid receptor modulator compounds and methods
US08/463,231 US5688808A (en)	1994-12-22	1995-06-05	Steroid receptor modulator compounds and methods
US08/465,556 US5696133A (en)	1994-12-22	1995-06-05	Steroid receptor modulator compounds and methods
US08/464,360 US5693646A (en)	1994-12-22	1995-06-05	Steroid receptor modulator compounds and methods
US08/464,541 US5688810A (en)	1994-12-22	1995-06-05	Steroid receptor modulator compounds and methods
PCT/US1995/016096 WO1996019458A2 (en)	1994-12-22	1995-12-13	Steroid receptor modulator compounds and methods

Publications (1)

Publication Number	Publication Date
BR9510486A true BR9510486A (pt)	1998-06-02

Family

ID=27575415

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR9510486A BR9510486A (pt)	1994-12-22	1995-12-13	Compostos moduladores de receptores de esteróide e métodos

Country Status (17)

Country	Link
EP (7)	EP1043326A1 (pt)
JP (2)	JPH10510840A (pt)
CN (2)	CN1626534A (pt)
AT (2)	ATE252560T1 (pt)
AU (1)	AU717251B2 (pt)
BR (1)	BR9510486A (pt)
CA (1)	CA2208347A1 (pt)
CZ (1)	CZ176197A3 (pt)
DE (2)	DE69533180T2 (pt)
DK (1)	DK0800519T3 (pt)
ES (1)	ES2208699T3 (pt)
HU (1)	HUT78117A (pt)
NO (5)	NO310617B1 (pt)
NZ (1)	NZ300739A (pt)
PT (1)	PT800519E (pt)
RU (1)	RU2191774C2 (pt)
WO (1)	WO1996019458A2 (pt)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE209207T1 (de) *	1996-06-27	2001-12-15	Ligand Pharm Inc	Androgen rezeptor modulator verbindungen und verfahren
US6017924A (en)	1996-06-27	2000-01-25	Ligand Pharmaceuticals Incorporated	Androgen receptor modulator compounds and methods
AUPO427196A0 (en) *	1996-12-19	1997-01-23	University Of Sydney, The	A method for preventing or controlling cataract
AU5729098A (en) *	1996-12-24	1998-07-17	Zymogenetics Inc.	Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
US6291442B1 (en)	1998-02-03	2001-09-18	The General Hospital Corporation	Pharmacological modulators of voltage-gated potassium ion channels
AU766441B2 (en) *	1998-02-13	2003-10-16	Abbott Laboratories	Glucocorticoid-selective anti-inflammatory agents
US6380207B2 (en)	1998-02-13	2002-04-30	Abbott Laboratories	Glucocortiocoid-selective antiinflammatory agents
US6506766B1 (en)	1998-02-13	2003-01-14	Abbott Laboratories	Glucocortiocoid-selective antinflammatory agents
US6001846A (en) *	1998-02-17	1999-12-14	Ligand Pharmaceuticals Incorporated	Process for the preparation of 1,2-dihydroquinolines
US6093825A (en) *	1998-05-27	2000-07-25	American Home Products	Methods for preparation of 1,2-dihydroquinolines
US6093826A (en) *	1998-06-08	2000-07-25	Ligand Pharmaceuticals Incorporated	Process for the preparation of C(5)-substituted 1,2-dihydro-5H-chromeno[3,4-f] quinolines
WO1999063980A1 (en)	1998-06-12	1999-12-16	Ligand Pharmaceuticals Inc.	Treatment of anti-estrogen resistant breast cancer using rxr modulators
US6339098B1 (en)	1999-05-04	2002-01-15	American Home Products Corporation	2,1-benzisothiazoline 2,2-dioxides
US6380235B1 (en)	1999-05-04	2002-04-30	American Home Products Corporation	Benzimidazolones and analogues
US6319912B1 (en)	1999-05-04	2001-11-20	American Home Products Corporation	Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6462032B1 (en)	1999-05-04	2002-10-08	Wyeth	Cyclic regimens utilizing indoline derivatives
US6391907B1 (en)	1999-05-04	2002-05-21	American Home Products Corporation	Indoline derivatives
US6417214B1 (en)	1999-05-04	2002-07-09	Wyeth	3,3-substituted indoline derivatives
US6444668B1 (en)	1999-05-04	2002-09-03	Wyeth	Combination regimens using progesterone receptor modulators
CZ20013951A3 (cs) *	1999-05-04	2002-05-15	American Home Products Corporation	Deriváty cyklokarbamátu jako modulátory receptoru pro progesteron
US6380178B1 (en)	1999-05-04	2002-04-30	American Home Products Corporation	Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6423699B1 (en)	1999-05-04	2002-07-23	American Home Products Corporation	Combination therapies using benzimidazolones
WO2000066560A1 (en) *	1999-05-04	2000-11-09	American Home Products Corporation	Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6358948B1 (en)	1999-05-04	2002-03-19	American Home Products Corporation	Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6369056B1 (en)	1999-05-04	2002-04-09	American Home Products Corporation	Cyclic urea and cyclic amide derivatives
US6329416B1 (en)	1999-05-04	2001-12-11	American Home Products Corporation	Combination regimens using 3,3-substituted indoline derivatives
CN1131856C (zh) *	1999-05-04	2003-12-24	美国家庭用品有限公司	作为黄体酮受体调节剂的环硫代氨基甲酸酯衍生物
US6407101B1 (en)	1999-05-04	2002-06-18	American Home Products Corporation	Cyanopyrroles
US6306851B1 (en)	1999-05-04	2001-10-23	American Home Products Corporation	Cyclocarbamate and cyclic amide derivatives
US6399593B1 (en)	1999-05-04	2002-06-04	Wyeth	Cyclic regimens using cyclic urea and cyclic amide derivatives
US6355648B1 (en)	1999-05-04	2002-03-12	American Home Products Corporation	Thio-oxindole derivatives
US6358947B1 (en)	1999-05-04	2002-03-19	American Home Products Corporation	Tetracyclic progesterone receptor modulator compounds and methods
US6509334B1 (en)	1999-05-04	2003-01-21	American Home Products Corporation	Cyclocarbamate derivatives as progesterone receptor modulators
CN1353717A (zh) *	1999-05-04	2002-06-12	莱加制药公司	四环黄体酮受体调节剂化合物及其方法
US6498154B1 (en)	1999-05-04	2002-12-24	Wyeth	Cyclic regimens using quinazolinone and benzoxazine derivatives
KR20020038741A (ko)	1999-08-27	2002-05-23	윌리암 엘. 레스페스	안드로겐 수용체 조절 화합물 및 방법
US6566372B1 (en)	1999-08-27	2003-05-20	Ligand Pharmaceuticals Incorporated	Bicyclic androgen and progesterone receptor modulator compounds and methods
US6667313B1 (en)	1999-08-27	2003-12-23	Ligand Pharmaceuticals Inc.	8-substituted-6-triflouromethyl-9-pyrido [3,2-G] quinoline compounds as androgen receptor modulators
PT1229906E (pt) *	1999-08-31	2008-01-18	Bayer Schering Pharma Ag	Mesoprogestinas para o tratamento e prevenção de distúrbios ginecológicos hormonodependentes benignos
JP2003529545A (ja)	1999-09-14	2003-10-07	リガンド・ファーマシューティカルズ・インコーポレイテッド	改善された薬理学的プロファイルを有するｒｘｒモジュレーター
AU7558900A (en) *	1999-10-14	2001-04-23	Kaken Pharmaceutical Co., Ltd.	Tetrahydroquinoline derivatives
UA73119C2 (en)	2000-04-19	2005-06-15	American Home Products Corpoir	Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
US20040077605A1 (en)	2001-06-20	2004-04-22	Salvati Mark E.	Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7001911B2 (en)	2000-06-28	2006-02-21	Bristol-Myers Squibb Company	Fused cyclic modulators of nuclear hormone receptor function
BR0111298A (pt)	2000-06-28	2005-05-10	Bristol Myers Squibb Co	Moduladores seletivos dos receptores de andrógenos e métodos para identificação, projeto e uso dos mesmos
CA2413683A1 (en) *	2000-06-28	2002-01-03	Bristol-Myers Squibb Company	Fused cyclic compounds as modulators of nuclear hormone receptor function
SK2052003A3 (en) *	2000-08-23	2003-07-01	Akzo Nobel Nv	10-Aryl-11-Hbenzo [b]fluorene derivatives and analogs for medicinal use
AU2001286243A1 (en)	2000-09-14	2002-03-26	Kaken Pharmaceutical Co., Ltd.	Tetrahydroquinoline compounds
DK1319007T3 (da) *	2000-09-19	2006-06-19	Bristol Myers Squibb Co	Kondenserede heterocykliske succinimidforbindelser og analoger deraf, modulatorer af nukleær hormonreceptorfunktion
US6953679B2 (en)	2000-09-19	2005-10-11	Bristol-Myers Squibb Company	Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
US7214690B2 (en)	2001-02-23	2007-05-08	Ligand Pharmaceuticals Incorporated	Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods
US7026484B2 (en)	2001-02-23	2006-04-11	Ligand Pharmaceuticals Incorporated	Tricyclic androgen receptor modulator compounds and methods
US6608216B2 (en)	2001-06-29	2003-08-19	Abbott Laboratories	Process for the preparation of chiral glucocorticoid receptor agents
WO2003002548A1 (en) *	2001-06-29	2003-01-09	Abbott Laboratories	A process for the preparation of chiral glucocorticoid receptor agents
HRP20031080A2 (en) *	2001-07-02	2004-04-30	Akzo Nobel Nv	Tetrahydroquinoline derivatives
JP2003073374A (ja) *	2001-08-31	2003-03-12	Kaken Pharmaceut Co Ltd	２環性芳香族アミン誘導体
TW200301107A (en) *	2001-12-13	2003-07-01	Wyeth Corp	Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents
AU2002364082A1 (en)	2001-12-19	2003-07-09	Bristol-Myers Squibb Company	Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
JP2005519897A (ja)	2002-01-14	2005-07-07	ベーリンガーインゲルハイムファーマシューティカルズインコーポレイテッド	グルココルチコイドミメチックス、その製造方法、それを含む医薬製剤及びその使用
TW200304371A (en)	2002-02-22	2003-10-01	Akzo Nobel Nv	Substituted 10-ary1-11H-benzo [b] fluorenes and 7-ary1-5, 6-dihydro-benz [a] anthracenes for selective effects on estrogen receptors
ATE533494T1 (de)	2002-02-28	2011-12-15	Univ Tennessee Res Foundation	Mehrfach substituierte selektive androgen- rezeptor-modulatoren und anwendungsverfahren dafür
WO2003078394A1 (en)	2002-03-15	2003-09-25	Eli Lilly And Company	Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
KR101022977B1 (ko)	2002-03-26	2011-03-18	베링거 인겔하임 파마슈티칼즈, 인코포레이티드	글루코코르티코이드 모사체, 이의 제조방법, 약제학적조성물 및 이의 용도
US7268152B2 (en)	2002-03-26	2007-09-11	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
CN1315836C (zh) *	2002-04-26	2007-05-16	奥索-麦克尼尔药品公司	用作雄激素受体调节剂的2－(喹诺酮基)－稠合杂环
US7405234B2 (en)	2002-05-17	2008-07-29	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
US7186864B2 (en)	2002-05-29	2007-03-06	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en)	2002-06-06	2006-07-11	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE60322713D1 (de) *	2002-08-21	2008-09-18	Boehringer Ingelheim Pharma	Substituierte dihydrochinoline als glucocorticoid-mmimetika,verfahren zu deren herstellung, pharmazeutische zubereitungen und deren verwendung
EP2298315A1 (en)	2002-08-28	2011-03-23	Harbor BioSciences, Inc.	Therapeutic treatment methods
AU2003258050A1 (en)	2002-10-11	2004-05-04	Ligand Pharmaceuticals Incorporated	5-cycloalkenyl 5h-chromeno(3,4-f)quinoline derivatives as selective progesterone receptor modulator compounds
DE20301728U1 (de)	2002-10-11	2004-03-11	Ligand Pharmaceuticals, Inc., San Diego	5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen
MXPA05003800A (es)	2002-10-11	2005-06-08	Ligand Pharm Inc	5-(1¦,1¦-cicloalquil/alquenil)metiliden 1,2-dihidro-5h- cromeno[3,4f]quinolinas como compuestos moduladores de receptor de progesterona selectivos.
EP1567487A4 (en)	2002-11-15	2005-11-16	Bristol Myers Squibb Co	OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
TWI306855B (en)	2002-12-20	2009-03-01	Organon Nv	Tetrahydroquinoline derivatives
TWI322012B (en) *	2002-12-20	2010-03-21	Organon Nv	Tetrahydroquinoline derivatives
RU2005124558A (ru)	2003-01-03	2006-04-10	Берингер Ингельхайм Фармасьютиклз, Инк. (Us)	Производные 1-пропанола и 1-пропиламина и их применение в качестве глюкокортикоидных лигандов
CN1795177A (zh) *	2003-03-28	2006-06-28	辉瑞产品公司	作为治疗动脉粥样硬化和肥胖症的cetp抑制剂的 1 , 2 , 4 , －取代的1，2，3，4，－四氢－和1，2二氢－喹啉以及1， 2 , 3 ， 4－四氢－喹喔啉衍生物
CA2536349A1 (en)	2003-08-22	2005-03-03	Ligand Pharmaceuticals Incorporated	6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
UY28526A1 (es)	2003-09-24	2005-04-29	Boehringer Ingelheim Pharma	Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
CA2542741A1 (en)	2003-10-16	2005-05-06	Boehringer Ingelheim Pharmaceuticals, Inc.	Stereoselective synthesis of certain trifluoromethyl-substituted alcohols
US7256208B2 (en)	2003-11-13	2007-08-14	Bristol-Myers Squibb Company	Monocyclic N-Aryl hydantoin modulators of androgen receptor function
US7820702B2 (en)	2004-02-04	2010-10-26	Bristol-Myers Squibb Company	Sulfonylpyrrolidine modulators of androgen receptor function and method
US7388027B2 (en)	2004-03-04	2008-06-17	Bristol-Myers Squibb Company	Bicyclic compounds as modulators of androgen receptor function and method
US7696241B2 (en)	2004-03-04	2010-04-13	Bristol-Myers Squibb Company	Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en)	2004-03-04	2009-12-01	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
US8519158B2 (en)	2004-03-12	2013-08-27	Ligand Pharmaceuticals Incorporated	Androgen receptor modulator compounds and methods
US7795272B2 (en)	2004-03-13	2010-09-14	Boehringer Ingelheim Pharmaceutical, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
CN101052641A (zh)	2004-09-07	2007-10-10	惠氏公司	6H－[1]苯并吡喃并[4,3－b]喹啉及其作为雌激素药物的用途
US7741361B2 (en)	2004-12-27	2010-06-22	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7709516B2 (en)	2005-06-17	2010-05-04	Endorecherche, Inc.	Helix 12 directed non-steroidal antiandrogens
CN101137655A (zh)	2005-06-17	2008-03-05	配体药物公司	雄激素受体调节剂化合物和方法
TWI375676B (en) *	2005-08-29	2012-11-01	Msd Oss Bv	Non-steroidal glucocorticoid receptor modulators
CN101263119B (zh) *	2005-09-14	2014-04-09	参天制药株式会社	具有糖皮质激素受体结合活性的1，2-二氢喹啉衍生物
JP4825636B2 (ja) *	2005-09-14	2011-11-30	参天製薬株式会社	グルココルチコイド受容体結合活性を有する新規１，２−ジヒドロキノリン誘導体
WO2007075884A2 (en) *	2005-12-21	2007-07-05	Ligand Pharmaceuticals Incorporated	Androgen receptor modulator compounds and methods
NZ570533A (en) *	2006-03-03	2011-02-25	Orion Corp	Compounds useful as Selective androgen receptor modulators (SARM), in particular (2S)-3-(4-cyano-3-fluorophenoxy)-N-(4-cyano-3-methylphenyl)-2-hydroxy-2-methylpropionamide useful in hormonal therapy
US8008497B2 (en)	2006-11-14	2011-08-30	Santen Pharmaceutical Co., Ltd.	1,2-dihydroquinoline derivative having (substituted phenyl or substituted heterocyclic) carbonyloxy lower alkyl group and ester-introduced phenyl group as substituents
JP2010512331A (ja)	2006-12-06	2010-04-22	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	グルココルチコイド模倣薬、それらの製造方法、医薬組成物、及びこれらの使用
TWI410422B (zh) *	2007-01-15	2013-10-01	Mitsubishi Tanabe Pharma Corp	縮合四氫喹啉衍生物及其醫藥用途
JP2008255112A (ja) *	2007-03-13	2008-10-23	Santen Pharmaceut Co Ltd	２，２，４−トリメチル−６−フェニル−１，２−ジヒドロキノリン誘導体からなるグルココルチコイド受容体アゴニスト
US9284345B2 (en)	2007-04-12	2016-03-15	Endorecherche, Inc.	17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
WO2009103007A2 (en) *	2008-02-13	2009-08-20	Ligand Pharmaceuticals Incorporated	Steroid hormone receptor modulator compounds and methods
WO2009139361A1 (ja)	2008-05-12	2009-11-19	参天製薬株式会社	置換オキシ基を有する２，２，４－トリメチル－６－フェニル－１，２－ジヒドロキノリン誘導体からなるグルココルチコイド受容体アゴニスト
EP2130831A1 (en)	2008-06-06	2009-12-09	InterMed Discovery GmbH	CDC25 inhibitors
ATE541846T1 (de)	2008-06-06	2012-02-15	Boehringer Ingelheim Int	Glucocorticoidmimetika, verfahren zu deren herstellung, pharmazeutische zusammensetzungen und anwendungen davon
US8729097B2 (en)	2008-10-06	2014-05-20	The Johns Hopkins University	Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and SIRT1, and methods of treating disorders
CN103613538B (zh) *	2013-11-22	2015-05-20	山东斯递尔化工科技有限公司	一种2,2,4-三甲基-1,2-二氢化喹啉聚合体的催化合成工艺
US9682960B2 (en)	2013-12-19	2017-06-20	Endorecherche, Inc.	Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
CN107530435A (zh)	2015-03-02	2018-01-02	科赛普特治疗学股份有限公司	使用糖皮质激素受体拮抗剂和生长抑素治疗acth分泌型肿瘤
WO2016160969A1 (en)	2015-03-30	2016-10-06	Corcept Therapeutics, Inc.	Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
KR20180052120A (ko)	2015-08-13	2018-05-17	코어셉트 쎄라퓨틱스, 잉크.	Acth-의존성 쿠싱 증후군을 감별 진단하는 방법
KR102197526B1 (ko)	2016-01-19	2020-12-31	코어셉트 쎄라퓨틱스 인코포레이티드	이소성 쿠싱 증후군의 감별 진단
CN106397317B (zh) *	2016-09-26	2019-03-22	天津师范大学	1,2,3,4-四氢喹啉化合物及其合成方法与应用
CA3055076C (en)	2017-03-31	2022-02-22	Corcept Therapeutics, Inc.	Glucocorticoid receptor modulators to treat cervical cancer
JP7670462B2 (ja)	2017-06-20	2025-04-30	コーセプトセラピューティクス，インコーポレイテッド	選択的グルココルチコイドレセプターモジュレーターを使用して神経上皮腫瘍を処置する方法
CN107805248A (zh) *	2017-11-01	2018-03-16	长春海谱润斯科技有限公司	一种含有苯并咪唑结构的衍生物及其制备方法和有机电致发光器件
CN111499607B (zh) *	2019-01-30	2022-04-19	哈尔滨工业大学（深圳）	一种六元芳基内酯或六元芳基内酰胺化合物的制备方法
JP2022529341A (ja)	2019-04-19	2022-06-21	リガンド・ファーマシューティカルズ・インコーポレイテッド	化合物の結晶形、および化合物の結晶形を生成する方法
AU2021400069A1 (en)	2020-12-18	2023-07-06	Instil Bio (Uk) Limited	Processing of tumor infiltrating lymphocytes
CN119409635B (zh) *	2024-11-04	2026-01-09	河南师范大学	具有抗癌活性的氟代甲基取代茚并[1,2-b]吡啶类化合物及其合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3635941A (en) *	1969-04-01	1972-01-18	Eastman Kodak Co	Disperse mono azo dyes containing an acylamidotetrahydroquinoline group
GB1379387A (en) *	1970-12-11	1975-01-02	Agfa Gevaert	Photoconductive recording materials
US3907507A (en) *	1971-04-26	1975-09-23	Heliodoro Monroy Rivera	Novel apparatus for the obtention of substituted 1,2-dihydroquinolines
GB8619902D0 (en) *	1986-08-15	1986-09-24	Pfizer Ltd	Quinolone cardiac stimulants
NZ221729A (en) *	1986-09-15	1989-07-27	Janssen Pharmaceutica Nv	Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
GB8709448D0 (en) *	1987-04-21	1987-05-28	Pfizer Ltd	Heterobicyclic quinoline derivatives
DE69132006T2 (de) *	1990-11-30	2000-08-03	Otsuka Pharmaceutical Co., Ltd.	Thiazolederivate als inhibitoren von aktivem sauerstoff
JPH04316557A (ja) *	1991-04-16	1992-11-06	Kyorin Pharmaceut Co Ltd	６−アリール環状アントラニル酸誘導体
RU2032685C1 (ru) *	1991-12-16	1995-04-10	Центр по химии лекарственных средств	Производные пиридо (3,2-а)карбазола, обладающие кардиотонической активностью
JP2686887B2 (ja) *	1992-08-11	1997-12-08	キッセイ薬品工業株式会社	ピペリジノ−３，４−ジヒドロカルボスチリル誘導体

1995
- 1995-12-13 NZ NZ300739A patent/NZ300739A/xx unknown
- 1995-12-13 EP EP00113830A patent/EP1043326A1/en not_active Withdrawn
- 1995-12-13 EP EP95944089A patent/EP0800519B1/en not_active Expired - Lifetime
- 1995-12-13 WO PCT/US1995/016096 patent/WO1996019458A2/en not_active Ceased
- 1995-12-13 CA CA002208347A patent/CA2208347A1/en not_active Abandoned
- 1995-12-13 AU AU45977/96A patent/AU717251B2/en not_active Ceased
- 1995-12-13 AT AT95944089T patent/ATE252560T1/de not_active IP Right Cessation
- 1995-12-13 JP JP8519861A patent/JPH10510840A/ja not_active Ceased
- 1995-12-13 DK DK95944089T patent/DK0800519T3/da active
- 1995-12-13 BR BR9510486A patent/BR9510486A/pt not_active IP Right Cessation
- 1995-12-13 EP EP00113915A patent/EP1041066A1/en not_active Withdrawn
- 1995-12-13 EP EP00113914A patent/EP1041071A1/en not_active Withdrawn
- 1995-12-13 CN CNA2004100740784A patent/CN1626534A/zh active Pending
- 1995-12-13 EP EP03023907A patent/EP1382597A3/en not_active Withdrawn
- 1995-12-13 EP EP00113829A patent/EP1043325B1/en not_active Expired - Lifetime
- 1995-12-13 ES ES95944089T patent/ES2208699T3/es not_active Expired - Lifetime
- 1995-12-13 PT PT95944089T patent/PT800519E/pt unknown
- 1995-12-13 RU RU97112141/04A patent/RU2191774C2/ru not_active IP Right Cessation
- 1995-12-13 CZ CZ971761A patent/CZ176197A3/cs unknown
- 1995-12-13 AT AT00113829T patent/ATE269336T1/de not_active IP Right Cessation
- 1995-12-13 EP EP00113916A patent/EP1043315A1/en not_active Withdrawn
- 1995-12-13 CN CNB951977024A patent/CN1172917C/zh not_active Expired - Fee Related
- 1995-12-13 DE DE69533180T patent/DE69533180T2/de not_active Expired - Fee Related
- 1995-12-13 DE DE69531998T patent/DE69531998T2/de not_active Expired - Fee Related
- 1995-12-13 HU HU9702305A patent/HUT78117A/hu unknown
1997
- 1997-06-06 NO NO19972591A patent/NO310617B1/no unknown
2000
- 2000-07-07 NO NO20003534A patent/NO312162B1/no unknown
- 2000-07-10 NO NO20003552A patent/NO313049B1/no unknown
- 2000-07-10 NO NO20003551A patent/NO312098B1/no unknown
- 2000-07-10 NO NO20003550A patent/NO20003550D0/no not_active Application Discontinuation
2007
- 2007-02-28 JP JP2007048504A patent/JP2007217418A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
EP0800519A1 (en)	1997-10-15
EP1043325A1 (en)	2000-10-11
NO20003551L (no)	1997-08-14
CN1172917C (zh)	2004-10-27
EP1041066A1 (en)	2000-10-04
JPH10510840A (ja)	1998-10-20
NO20003534D0 (no)	2000-07-07
NO313049B1 (no)	2002-08-05
NO20003550L (no)	1997-08-14
EP1041071A1 (en)	2000-10-04
NO972591D0 (no)	1997-06-06
CA2208347A1 (en)	1996-06-27
NO20003534L (no)	1997-08-14
DK0800519T3 (da)	2004-03-01
WO1996019458A2 (en)	1996-06-27
RU2191774C2 (ru)	2002-10-27
NO310617B1 (no)	2001-07-30
NO312162B1 (no)	2002-04-02
JP2007217418A (ja)	2007-08-30
EP1043315A1 (en)	2000-10-11
AU717251B2 (en)	2000-03-23
WO1996019458A3 (en)	1996-12-12
PT800519E (pt)	2004-03-31
NO20003550D0 (no)	2000-07-10
ATE252560T1 (de)	2003-11-15
NZ300739A (en)	2000-05-26
CN1626534A (zh)	2005-06-15
EP1382597A2 (en)	2004-01-21
NO20003552D0 (no)	2000-07-10
AU4597796A (en)	1996-07-10
NO20003552L (no)	1997-08-14
HUT78117A (hu)	1999-11-29
DE69533180T2 (de)	2005-07-14
ES2208699T3 (es)	2004-06-16
EP0800519B1 (en)	2003-10-22
CZ176197A3 (cs)	1998-09-16
DE69533180D1 (de)	2004-07-22
NO972591L (no)	1997-08-14
NO312098B1 (no)	2002-03-18
NO20003551D0 (no)	2000-07-10
EP1382597A3 (en)	2004-04-07
DE69531998D1 (de)	2003-11-27
CN1175247A (zh)	1998-03-04
EP1043325B1 (en)	2004-06-16
DE69531998T2 (de)	2004-07-22
EP1043326A1 (en)	2000-10-11
ATE269336T1 (de)	2004-07-15

Publication	Publication Date	Title
BR9510486A (pt)	1998-06-02	Compostos moduladores de receptores de esteróide e métodos
MX9704640A (es)	1997-10-31	Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion.
ES2168650T3 (es)	2002-06-16	Compuestos y metodos moduladores de receptores de androgenos.
WO2000066590A3 (en)	2001-02-08	Tetracyclic progesterone receptor modulator compounds and methods
DK0873295T3 (da)	2003-07-14	Dimer-selektive RXR-modulatorer og fremgangsmåder til deres anvendelse
DE69531403D1 (de)	2003-09-04	Allosterische modulatoren des nmda-rezeptors
BG106142A (en)	2002-05-31	Glucocorticoid receptor modulators
DE69728585D1 (de)	2004-05-13	Mittel gegen Juckreiz
EP0911321A3 (en)	2001-01-31	Compounds for the treatment of osteoporosis
BR9813028A (pt)	2000-08-15	Agonistas de prostaglandina e seu uso para tratar distúrbios nos ossos
DK0751939T3 (da)	2002-10-07	Naphthylamider som centralnervesystemmidler
DK1063995T3 (da)	2003-03-10	Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator
DK0874625T3 (da)	2005-06-20	Indanderivater til antipsykotiske præparater
EA199800867A1 (ru)	1999-02-25	Соединения тетрагидробетакарболина
CA2259031A1 (en)	1997-12-31	Androgen receptor modulator compounds and methods

Legal Events

Date	Code	Title	Description
2000-03-21	FA10	Dismissal: dismissal - article 33 of industrial property law
2000-06-13	HKFN	Application deemed withdrawn (deleted)
2005-06-14	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2005-10-25	B25G	Requested change of headquarter approved	Owner name: LIGAND PHARMACEUTICALS INCORPORATED (US) Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 20050035890-RJ DE 23.05.2005
2005-12-06	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2006-06-06	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2007-02-21	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2007-05-22	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/05/2007, OBSERVADAS AS CONDICOES LEGAIS.
2010-03-23	B24C	Patent annual fee: request for for restoration	Free format text: REFERENTE A(S) 14A ANUIDADES.
2013-04-30	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2183 DE 08/09/2009 E AO NAO RECOLHIMENTO DA 15A, 16A E 17A ANUIDADES.